Beneficial Effects of Mineralocorticoid Receptor Antagonism on Myocardial Fibrosis in an Experimental Model of the Myxomatous Degeneration of the Mitral Valve

Beneficial Effects of Mineralocorticoid Receptor Antagonism on Myocardial Fibrosis in an Experimental Model of the Myxomatous Degeneration of the Mitral Valve

Mitral valve prolapse (MVP) patients develop myocardial fibrosis that is not solely explained by volume overload, but the pathophysiology has not been defined. Mineralocorticoid receptor antagonists (MRAs) improve cardiac function by decreasing cardiac fibrosis in other heart diseases. We examined t...

Full description

Bibliographic Details
Main Authors:	Jaime Ibarrola, Mattie Garaikoetxea, Amaia Garcia-Peña, Lara Matilla, Eva Jover, Benjamin Bonnard, Maria Cuesta, Amaya Fernández-Celis, Frederic Jaisser, Natalia López-Andrés
Format:	Article
Language:	English
Published:	MDPI AG 2020-07-01
Series:	International Journal of Molecular Sciences
Subjects:	myxomatous degeneration cardiac fibrosis mineralocorticoid receptor antagonist collagen proteoglycans
Online Access:	https://www.mdpi.com/1422-0067/21/15/5372

Similar Items

Activation of the Interleukin-33/ST2 Pathway Exerts Deleterious Effects in Myxomatous Mitral Valve Disease
by: Amaia Garcia-Pena, et al.
Published: (2021-02-01)

Beneficial Effects of Mineralocorticoid Receptor Pathway Blockade against Endothelial Inflammation Induced by SARS-CoV-2 Spike Protein
by: Eva Jover, et al.
Published: (2021-06-01)

Sex-specific responses to mineralocorticoid receptor antagonism in hypertensive African American males and females
by: John S. Clemmer, et al.
Published: (2019-05-01)

Mineralocorticoid Receptor Antagonists
by: Ilaria Spoletini, et al.
Published: (2019-01-01)

Echocardiographic Investigation of Canine Myxomatous Mitral Valvular Disease
by: Wesselowski, Sonya Rae
Published: (2014)

Advances in the understanding of the pathogenesis, progression and diagnosis of myxomatous mitral valve disease in dogs
by: Richard K. Burchell, et al.
Published: (2014-08-01)

Mitral annulus dynamics in myxomatous mitral valve disease
by: Maria-Magdalena Gurzun, et al.
Published: (2021-03-01)

Mineralocorticoid receptors in the pathophysiology of vascular inflammation and atherosclerosis.
by: Mary Elizabeth Moss, et al.
Published: (2015-09-01)

Asymptomatic Myxomatous Degeneration of the Mitral Valve, in a Young Male
by: Opris Carmen, et al.
Published: (2020-12-01)

Genomic analysis in patients with myxomatous mitral valve prolapse: current state of knowledge
by: S. Gasser, et al.
Published: (2018-02-01)

Mediators of intracellular interactions and endothelial function in myxomatous mitral valve prolapse
by: A. V. Yagoda, et al.
Published: (2013-02-01)

Medical management of myxomatous mitral valve disease: An evidence-based veterinary medicine approach
by: Richard K. Burchell, et al.
Published: (2014-10-01)

Mineralocorticoid receptor antagonist use following heart failure hospitalization
by: Jason M. Duran, et al.
Published: (2020-04-01)

Mineralocorticoid Receptor Signaling Contributes to Normal Muscle Repair After Acute Injury
by: J. Spencer Hauck, et al.
Published: (2019-10-01)

Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015
by: Yu F Osmolovskaya, et al.
Published: (2015-09-01)

Comparative Transcriptomic Profiling and Gene Expression for Myxomatous Mitral Valve Disease in the Dog and Human
by: Greg R. Markby, et al.
Published: (2017-07-01)

Reliability of symmetric dimethylarginine in dogs with myxomatous mitral valve disease as kidney biomarker
by: Alice Savarese, et al.
Published: (2018-08-01)

Myxomatous form of lupus vulgaris in ear: A rare presentation
by: C Chandrakala, et al.
Published: (2019-01-01)

Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists
by: Yugar-Toledo JC, et al.
Published: (2017-10-01)

MINERALOCORTICOID RECEPTOR ANTAGONISTS THERAPY IN RESISTANT HYPERTENSION: TIME TO IMPLEMENT NEW GUIDELINES?
by: Giuseppe eMaiolino, et al.
Published: (2015-02-01)

Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology
by: Sofia S. Pereira, et al.
Published: (2021-04-01)

Mineralocorticoid receptor antagonists in the treatment of patients with heart failure after myocardial infarction and those with chronic heart failure
by: S N Tereshchenko, et al.
Published: (2013-12-01)

The Role of Mineralocorticoid Receptor Signaling in Genitourinary Cancers
by: Yujiro Nagata, et al.
Published: (2019-02-01)

Diagnostic value of echocardiographic indices of left atrial and ventricular morphology in dogs with myxomatous mitral valve disease (MMVD)
by: R. M. Trofimiak, et al.
Published: (2021-03-01)

Infectious agents is a risk factor for myxomatous mitral valve degeneration: A case control study
by: Marcos Gradim Tiveron, et al.
Published: (2017-04-01)

Mineralocorticoid receptor antagonists in chronic central serous chorioretinopathy
by: Ana Sanhueza, et al.
Published: (2020-09-01)

Expression Profiling of Circulating MicroRNAs in Canine Myxomatous Mitral Valve Disease
by: Qinghong Li, et al.
Published: (2015-06-01)

Evaluation of endothelial cell-specific molecule-1 as a biomarker of glycocalyx damage in canine myxomatous mitral valve disease
by: An, J.-H, et al.
Published: (2022)

Does Mineralocorticoid Receptor Antagonism Prevent Calcineurin Inhibitor-Induced Nephrotoxicity?
by: Line Aas Mortensen, et al.
Published: (2017-11-01)

Myxomatous Mitral Valve Disease with Mitral Valve Prolapse and Mitral Annular Disjunction: Clinical and Functional Significance of the Coincidence
by: Nina C. Wunderlich, et al.
Published: (2021-01-01)

Comparative transcriptomic profiling of myxomatous mitral valve disease in the cavalier King Charles spaniel
by: G. R. Markby, et al.
Published: (2020-09-01)

Increased Infiltration of Extra-Cardiac Cells in Myxomatous Valve Disease
by: Kimberly Sauls, et al.
Published: (2015-07-01)

MINERALOCORTICOID ANTAGONISM: SELECTIVENESS GIVES MORE OPPORTUNITIES FOR HEART FAILURE MANAGEMENT
by: V. N. Soboleva, et al.
Published: (2015-01-01)

Prognostic impact of additional mineralocorticoid receptor antagonists in octogenarian heart failure patients
by: Takuro Abe, et al.
Published: (2020-10-01)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
by: Nina Vodošek Hojs, et al.
Published: (2021-06-01)

Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
by: Yuta Tezuka, et al.
Published: (2021-03-01)

Differential MicroRNA Expression Profile in Myxomatous Mitral Valve Prolapse and Fibroelastic Deficiency Valves
by: Yei-Tsung Chen, et al.
Published: (2016-05-01)

Mineralocorticoid receptor antagonists: new extended roles in cardio- and nephroprotection
by: A. M. Esayan, et al.
Published: (2018-04-01)

Disease Severity-Associated Gene Expression in Canine Myxomatous Mitral Valve Disease Is Dominated by TGFβ Signaling
by: Greg R. Markby, et al.
Published: (2020-04-01)

Utility of radiographic measurements to predict echocardiographic left heart enlargement in dogs with preclinical myxomatous mitral valve disease
by: Megan H. Poad, et al.
Published: (2020-09-01)

Cannot write session to /tmp/vufind_sessions/sess_rs7srpu56at6kh03c6e9na8h93